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DETAILS ON PARTICIPATING STUDIES: 
Fourteen genome-wide association studies (GWAS) consisting of individuals of European 
descent from Europe and the United States contributed to the discovery phase of this study. 
To extend our analyses, we genotyped select variants representing nine loci in an additional 
cohort (PREVEND). All studies received approval from the appropriate institutional review 
committees, and the subjects in each cohort provided written informed consent.    
AGES: The Age, Gene/Environment Susceptibility (AGES) Reykjavik Study was 
initiated to examine genetic susceptibility and gene/environment interaction as these 
contribute to phenotypes common in old age, and represents a continuation of the Reykjavik 
Study cohort begun in 1967 and is comprised of 5776 randomly recruited  survivors from the 
original cohort.  QRS interval duration was automatically measured from 12-lead 
electrocardiograms using the Marquette 12 SL analysis program (General Electric Marquette 
Medical Division, Milwaukee, Wisconsin, USA).    
ARIC:  The Atherosclerosis Risk in Communities study (http://www.cscc.unc.edu/aric/) 
includes 15,792 men and women from four communities in the United States (Jackson, 
Mississippi; Forsyth County, North Carolina; Washington County, Maryland; suburbs of 
Minneapolis, Minnesota) enrolled in 1987–1989 and prospectively followed.  ECGs were 
recorded at baseline using MAC PC ECG machines (Marquette Electronics) and processed 
initially by the Dalhousie ECG program in a central laboratory at the EPICORE Center 
(University of Alberta). Processing was later repeated for the present study using the GE 
Marquette 12-SL program (2001 version) at the EPICARE Center (Wake Forest University).  
All ECGs were visually inspected for technical errors and inadequate quality. QRS interval 
was measured automatically from baseline ECGs.   
BRIGHT:  The MRC BRIGHT study (http://www.brightstudy.ac.uk/) comprises 2000 
severely hypertensive probands ascertained from families with multiplex affected sibships or 
as parent-offspring trios. Case ascertainment and phenotyping has been described 
previously.  Briefly, cases have BP readings ≥150/100 mmHg based on one reading or 
≥145/95 mmHg based on the mean of three readings.  Twelve-lead ECG recordings 
(Siemens-Sicard 440; http://www.brightstudy.ac.uk/info/sop04.html), which produces an 
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automated measurement of the QRS interval, were available for all subjects. All data were 
transferred from each recruitment centre by electronic modem to electrophysiologists from 
the West of Scotland Primary Prevention Study (Professor Peter MacFarlane) for central 
reporting. All individuals included in the analysis were of white British ancestry (up to level of 
grandparents).  
CHS: The Cardiovascular Health Study (www.chs-nhlbi.org) is a prospective, 
longitudinal cohort study of risk factors for cardiovascular disease in the elderly, was begun in 
1989 and included 4,925 self-described White participants.  People 65 years of age or older 
were recruited from four field centers in the United States. The CHS study sample used in 
this analysis includes participants without clinically-recognized cardiovascular disease at 
baseline who described their race as White, consented to genetic testing, and had DNA 
available for genotyping. Study electrocardiograms were recorded using MAC PC ECG 
machines (Marquette Electronics, Milwaukee, Wisconsin) in all clinical centers. ECGs were 
initially processed in a central laboratory at the EPICORE Center (University of Alberta, 
Edmonton, Alberta, Canada) and during later phases of the study, at the EPICARE Center 
(Wake Forest University, Winston-Salem, North Carolina). All ECGs were visually inspected 
for technical errors and inadequate quality. QRS interval was measured using the baseline 
ECG for eligible subjects.   Initial ECG processing was done by the Dalhousie ECG program, 
and processing was later repeated with the 2001 version of the GE Marquette 12-SL program 
(GE Marquette, Milwaukee, Wisconsin). 
ERF: The Erasmus Rucphen Family study is comprised of a family-based cohort 
embedded in the Genetic Research in Isolated Populations (GRIP) program in the southwest 
of the Netherlands.  The aim of this program is to identify genetic risk factors for the 
development of complex disorders. In ERF, twenty-two families that had a minimum of five 
children baptized in the community church between 1850 and 1900 were identified with the 
help of detailed genealogical records. All living descendants of these couples, and their 
spouses, were invited to take part in the study. Comprehensive interviews, questionnaires, 
and examinations were completed at a research center in the area; approximately 3,200 
individuals participated.  Examinations included 12 lead ECG measurements.  
Electrocardiograms were recorded on ACTA electrocardiographs (ESAOTE, Florence, Italy) 
and digital measurements of the QRS intervals were made using the Modular ECG Analysis 
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System (MEANS).  The QRS detector of MEANS operates on multiple simultaneously 
recorded leads, which are transformed to a detection function that brings out the QRS 
complexes among the other parts of the signal. Data collection started in June 2002 and was 
completed in February 2005. In the current analyses, 1466 participants for whom complete 
phenotypic, genotypic and genealogical information was available were studied.  
FHS: The Framingham Heart Study (http://www.framinghamheartstudy.org/ ) is a 
community-based, longitudinal cohort study comprising three generations of individuals in 
multigenerational pedigrees and additional unrelated individuals.   The current study included 
individuals from Generation 1 (11th examination), Generation 2 (1st examination) and 
Generation 3 (1st examination).  In FHS, paper electrocardiograms recorded on Marquette 
machines were scanned and digital caliper measurements were made using proprietary 
software (eResearchTechnology, generations 1 and 2) or using Rigel 1.7.2. (AMPS, LLC, 
New York, NY, USA, generation 3).  The QRS duration was measured from the Q-onset to S-
offset in two cardiac cycles from lead II and averaged.  
KORA F3 and S4:  The KORA study is a series of independent population-based 
epidemiological surveys of participants living in the city of Augsburg, Southern Germany, or 
the two adjacent counties.  All survey participants are residents of German nationality 
identified through the registration office and aged between 25 and 74 years at recruitment. 
The baseline survey KORA S3 was conducted in the years 1994/95 and KORA S4 in 1999-
2001. 3,006 participants from KORA S3 were reexamined in a 10-year follow-up (KORA F3) 
in the years 2004/05. Genomewide data for the analysis of the length of the QRS interval is 
available for random subsets of 1,644 persons from KORA F3 and 1,814 study participants 
from KORA S4. In both studies, 12-lead resting electrocardiograms were recorded with digital 
recording systems (F3: Mortara Portrait, Mortara Inc., Milwaukee, USA, S4: Hörmann Bioset 
9000, Hörmann Medizinelektronik, Germany).  
KORKULA:  The KORCULA study sampled Croatians from the Adriatic island of 
Korcula, between the ages of 18 and 88. The fieldwork was performed in 2007 in the eastern 
part of the island, targeting healthy volunteers from the town of Korčula and the villages of 
Lumbarda, Žrnovo and Račišće. Mortara ELI 350 was used in ECG recording.   
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MICROS:  The MICROS study (http://www.biomedcentral.com/1471-2350/8/29) is part of 
the genomic health care program 'GenNova' and was carried out in three villages of the Val 
Venosta on the populations of Stelvio, Vallelunga and Martello. This study was an extensive 
survey carried out in South Tyrol (Italy) in the period 2001-2003.  Study participants were 
volunteers from three isolated villages located in the Italian Alps, in a German-speaking 
region bordering with Austria and Switzerland. Due to geographical, historical and political 
reasons, the entire region experienced a prolonged period of isolation from surrounding 
populations. Genotyping was performed on just under 1400 participants with 1334 available 
for analysis after data cleaning. Information on participants’ health status was collected 
through a standardized questionnaire and clinical examinations, including digitized ECG 
measurements (Mortara Portrait, Mortara Inc., Milwaukee, USA). Individuals with identified U-
waves were excluded from analysis. The Mortara portrait determines QRS complex by a 
proprietary algorithm (Michelucci 2002). Laboratory data were obtained from standard blood 
analyses.   
ORCADES:  The Orkney Complex Disease Study (ORCADES) is an ongoing family-
based, cross-sectional study in the isolated Scottish archipelago of Orkney. Genetic diversity 
in this population is decreased compared to Mainland Scotland, consistent with high levels of 
endogamy historically. Participants included here were aged 18-92 years and came from a 
subgroup of ten islands. The Cardioview ECG device was used in the phenotyping.   
ROTTERDAM STUDY (RS1 and RS2):  The Rotterdam Study is a prospective 
population-based cohort study comprising 7,983 subjects aged 55 years or older (RS-I), 
which started in 1990. In 2000-2001, an additional 3,011 individuals aged 55 years or older 
were recruited (RS-II).28   In the RS-I and RS-II, electrocardiograms were recorded on ACTA 
electrocardiographs (ESAOTE, Florence, Italy) and digital measurements of the QRS 
intervals were made using the Modular ECG Analysis System (MEANS).   The QRS detector 
of MEANS operates on multiple simultaneously recorded leads, which are transformed to a 
detection function that brings out the QRS complexes among the other parts of the signal.  
SHIP:  The Study of Health in Pomerania (http://ship.community-medicine.de) is a 
longitudinal population-based cohort study in West Pomerania, a region in the northeast of 
Germany.  From the total population comprising 212,157 inhabitants in 1995, a two-stage 
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stratified cluster sample of adults aged 20 to 79 years was drawn. From the net sample of 
6265 eligible subjects, 4308 subjects (2192 women) of Caucasian origin participated in the 
baseline examination, SHIP-0 (response 68.8%).  For the present analyses both 
electrocardiographic and genotyping data were available from 2985 participants of the SHIP 
baseline cohort without exclusion criteria.  QRS intervals in SHIP were measured from 
digitally stored electrocardiograms (Personal 120LD, Esaote, Genova, Italy) using MEANS 
according to the method described above for the RS.  
SPLIT:  The SPLIT study samples Croatians from the town of Split, between the ages 
18 and 85. The sampling started in 2008, and continues throughout 2010. Mortara ELI 350 
was used in ECG recording.  
TWINSUK:  The Twins UK Registry (http://www.twinsuk.ac.uk) comprises unselected, 
mostly female volunteers ascertained from the general population through national media 
campaigns in the UK.  Means and ranges of quantitative phenotypes in Twins UK were 
similar to an age-matched singleton sample from the general population.  Zygosity was 
determined by standardized questionnaire and confirmed by DNA fingerprinting.  QRS 
duration data were available on 2,726 of these individuals measured automatically by the 
Cardiofax ECG-9020K (Nihon Kohden UK Ltd., Middlesex, UK).  
PREVEND:  The Prevention of REnal and Vascular ENd stage Disease (PREVEND) 
study is an ongoing prospective study investigating the natural course of increased levels of 
urinary albumin excretion and its relation to renal and cardiovascular disease. Inhabitants 28 
to 75 years of age (n=85,421) in the city of Groningen, The Netherlands, were asked to 
complete a short questionnaire, 47% responded, and individuals were then selected with a 
urinary albumin concentration of at least 10 mg/L (n = 7,768) and a randomly selected control 
group with a urinary albumin concentration less than 10 mg/L (n = 3,395). Details of the 
protocol have been described elsewhere (www.prevend.org). Standard 12-lead 
electrocardiograms were recorded with CardioPerfect equipment (Cardio 
Control; currently Welch Allyn, Delft, The Netherlands) and digital measurements of the QRS 
intervals were made using the Modular ECG Analysis System (MEANS). The QRS detector 
of MEANS operates on multiple simultaneously recorded leads, which are transformed to a 
detection function that brings out the QRS complexes among the other parts of the signal. 
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STUDY INVESTIGATORS: 
 
AGES (Age, Gene/Environment Susceptibility-Reykjavik Study): Albert Vernon Smith, Thor 
Aspelund, Lenore Launer, Tamara B. Harris, Vilmundur Gudnason  
ARIC (Atherosclerosis Risk in Communities Study): Alvaro Alonso, Man Li, Anna Köttgen, 
Aravinda Chakravarti, Elsayed Z. Soliman, Eric Boerwinkle, W.H. Linda Kao, Aaron R. 
Folsom, Dan E. Arking 
BRIGHT (British Genetics of Hypertension Study): Sandosh Padmanabhan, Toby Johnson, 
Patricia B. Munroe, Anna F. Dominiczak, Mark J. Caulfield, John M. Connell, Nilesh J. 
Samani 
Broad Institute: Paul I. W. de Bakker 
CHS (Cardiovascular Health Study): Nona Sotoodehnia, Kristin D. Marciante, Sina A. Gharib, 
Joshua C. Bis, Kenneth Rice, Bruce M. Psaty, Jerome I. Rotter, Susan R. Heckbert, David S. 
Siscovick 
Dutch eQTL: Jingyuan Fu, Xiaowen Lu, Lude Franke, Rudolf S.N. Fehrmann, Gerard te 
Meerman, Harry J.M. Groen, Rinse K. Weersma, Leonard H. van den Berg, Cisca Wijmenga, 
Roel A. Ophoff, Harold Snieder 
ERF (Erasmus Rucphen Family Study): Aaron Isaacs, Mark P.S. Sie, Gé van Herpen, Ben A. 
Oostra, Cornelia M. van Duijn  
Fishman Lab: Steven Giovannone, Jiaxiang Qu, Fang-Yu Liu, Glenn I. Fishman 
FHS (Framingham Heart Study): L. Adrienne Cupples, Daniel Levy, Jared W. Magnani, 
Christopher Newton-Cheh, Christopher J. O’Donnell, Amanda Ying Wang, Thomas J. Wang  
KORA (Kollaborative Gesundheitsforschung in der Region Ausgsburg): Martina Müller, Arne 
Pfeufer, Norman Klopp, Moritz F. Sinner, Siegfried Perz, H.-Erich Wichmann, Thomas 
Meitinger, Stefan Kääb 
MICROS (Micro Isolates in South Tyrol): Andrew A. Hicks, Christian Fuchsberger, Christine 
Schwienbacher, Peter P. Pramstaller, Claudia Volpato 
ORCADES (Orkney Complex Disease Study): Caroline Hayward, Sarah H. Wild, James F. 
Wilson 
PREVEND (Prevention of Renal and Vascular End stage Disease): Pim van der Harst, Irene 
Mateo Leach, Rudolf A. de Boer, Wiek H. van Gilst, Dirk J. van Veldhuisen, Gerjan Navis 
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RS (Rotterdam Study): Mark Eijgelsheim, Fernando Rivadeneira, Karol Estrada, Jan A. Kors, 
André G. Uitterlinden, Jacqueline C.M. Witteman, Albert Hofman, Bruno H Ch Stricker  
SHIP (Study of Health in Pomerania): Marcus Dörr, Alexander Teumer, Uwe Völker, Astrid 
Petersmann, Henry Völzke, Heyo K. Kroemer, Stephan B. Felix 
SPLIT and KORCULA: Ozren Polasek, Alan F. Wright, Igor Rudan, Harry Campbell 
TwinsUK: Ilja M. Nolte, Harold Snieder, Jingyuan Fu, Folkert W. Asselbergs, Timothy D. 
Spector, Yalda Jamshidi  
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SUPPLEMENTARY FIGURES: 
 
 
Supplementary Figure 1: Q-Q plot.  The quantile-quantile (Q-Q) plots demonstrate robust behavior in the bulk of the 
distribution (lower-left corner) (consistent with a modest GC of 1.05).  In the tail of the distribution, we observe a departure 
away from the null hypothesis, presumably due to the presence of true associations.  
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Supplementary Figure 2: Regional association plots.  Association results at each significantly associated locus.  Loci are 
displayed in the order listed in Table 1.  Each SNP is plotted with respect to its chromosomal location (x-axis) and its P-value 
(y-axis on the left). Each panel spans approximately ±500 kb around each index SNP and has known gene transcripts 
annotated at the bottom. The SNPs are colored according to their degree of linkage disequilibrium (r2) with the index variant 
which is highlighted with a red diamond and displayed by rs number and significance level achieved in the meta-analysis. The 
triangles indicate coding region SNPs.  The tall blue spikes indicate the recombination rate (y-axis on the right) at that region of 
the chromosome.  To the right of each association plot is the forest plot detailing the findings at the level of the individual study. 
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Supplementary Figure 3a: Cis expression-genotype association analysis. The most striking cis eQTLs were observed for 
probes in exonic regions of TKT (rs4687718, P=5.87x10-70) and CDKN1A (rs9470361, P=1.41x10-10) and an intronic probe for 
C6orf204 near PLN (rs11153730, P=1.54x10-10).  The y-axis indicates normalized expression data and the x-axis indicates the 
dosage genotype values.  NCBI genomic build 36 was used in probe numbering. 
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The -values in -4, corresponding to Bonferroni corrected bolded le is the coded allele.
Effect size (β) is reported in normalized units of gene expression per copy of the coded allele.  Chr, chromosome; AF, coded allele 
frequency; SE, standard error; HWE, Hardy-Weinberg equilibrium.  
P bold are significant at P<2.5x10 P<0.05. The  alle    
Supplementary Figure 3b: Cis expression-genotype association results 
Locus Index SNP Chr 
Coded/
Non-
coded 
Allele AF Gene ID 
Genomic 
location of 
probe eQTL β eQTL SE eQTL P 
13 rs4687718 3 A/G 0.11 TKT Exon -0.227 0.0128 5.87x10-70 
2 rs9470361 6 A/G 0.24 CDKN1A Exon -0.083 0.0129 1.41x10-10 
3 rs11153730 6 C/T 0.48 C6orf204 Intron 0.044 0.0069 1.54x10-10 
6 rs1362212 7 A/G 0.15 DPY19L1 Exon 0.036 0.0093 1.22x10-4 
   A/G  TBX20 Exon -0.016 0.0057 5.59x10-3 
11 rs991014 18 T/C 0.43 SETBP1 Exon 0.027 0.0081 9.03x10-4 
14 rs7562790 2 G/T 0.4 AC007401.2/FEZ2 Exon -0.025 0.0095 7.96x10-3 
22 rs17608766 17 C/T 0.16 NSF Intron 0.027 0.0105 9.49x10-3 
5 rs13165478 5 A/G 0.34 HAND1 Exon -0.01 0.004 9.82x10-3 
 
Supplementary Figure 3b : Cis expression-genotype association probe information 
Locus Index SNP Chr Position 
Coded/
Non-
coded 
Allele HWE P 
genotype_
Info ProbeID GeneID 
Transcript 
Start 
Transcript  
End 
13 rs4687718 3 53,257,343 A/G 0.56 0.85 6860202 TKT 53,233,715 53,266,078 
2 rs9470361 6 36,731,357 A/G 0.66 0.92 4230201 CDKN1A 36,753,465 36,764,086 
3 rs11153730 6 118,774,215 C/T 0.33 0.99 3170403 C6orf204 118,911,755 118,919,501 
6 rs1362212 7 35,271,831 A/G 0.85 0.95 3120379 DPY19L1 34,926,606 35,045,178 
    A/G  0.93 6330100 TBX20 35,207,567 35,261,283 
11 rs991014 18 40,693,884 T/C 0.46 1 5310079 SETBP1 40,513,861 40,899,771 
14 rs7562790 2 36,527,059 G/T 0.11 1 6200053 
AC007401.2/
FEZ2 36,619,732 36,656,875 
22 rs17608766 17 42,368,270 C/T 0.28 0.88 2370411 NSF 42,107,119 42,125,492 
5 rs13165478 5 153,849,233 A/G 0.11 0.86 3420035 HAND1 153,834,205 153,838,537 
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Supplementary Figure 4. Network map. In silico relational network linking the loci associated with QRS interval duration. 
Most loci meeting genome-wide significance mapped to this network (shown in magenta).  For loci where either multiple genes 
were independently associated with QRS interval duration (SCN5A and SCN10A in locus 1) or where it was difficult to discern 
to which of several genes the association signal might map (loci 3, 5, 12, 13, 15, 21, or 22), several genes (listed in Table 1 for 
each of the loci) were included in the model.  Of these seven latter loci, three (loci 13, 15, and 21) had 2 gene members map to 
the network. All interactions depicted in this relational network represent direct gene product interactions obtained from curated 
databases.  To ensure that the interactome spanned across the maximum number of QRS-associated genes, several nodes 
(shown in yellow) were added to the network based on the strength of their connectivity with the original loci.  Linker nodes 
were added only if they connected to a minimum of two network nodes, without bias in regards to function. The minimum 
number of linkers required to connect network nodes was selected. Our network analysis shows that many of the genetic loci 
associated with QRS duration interact with each other and are likely to be functionally linked, although the relevance of these 
relationships in the human heart needs to be experimentally assessed. 
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SUPPLEMENTARY TABLES: 
 
*The KORA and RS studies both have two separate cohorts.  **  for the candidate SNP extension 
genotyping only.  All other studies were included in the GWAS meta-analysis. 
PREVEND study participants were used
Supplementary Table 1a:  Study participant characteristics 
Characteristic AGES ARIC BRIGHT CHS SPLIT KORCULA ERF FHS 
 
N, Participants with ECG and 
genotype data 3188 9013 1566 3271 433 428 1591 
7950 
N, Participants after exclusion 2251 8085 1302 2845 395 378 1466 7499 
Sex, women, % 64.0 54.4 63.0 62.8 63.5 62.5 59.5 54.1 
Age, years, mean 76.0 54.0 58.8 72.1 49.3 54.5 47.8 39.2 
Age, years, range 66 – 95 44 – 66 21 – 89 65 – 94 18 – 85 18 – 88 18 – 83 19 – 79 
QRS interval, ms, mean 90.4 96.2 92.9 88.3 96.1 95.9 97.1 87.2 
QRS interval, ms, range 60 – 120 61 – 120 66 – 118 56 – 120 70 – 120 76 – 119 68 – 120 59 - 120 
Height, cm, mean 166.1 168.6 170.0 164.3 171.2 168.0 166.5 168.9 
BMI, kg/m2, mean 27.0 26.8 27.4 26.2 26.7 28.0 26.7 26.2 
Hypertension, % 77.8 24.1 100 51.9 25.2 28.8 15 8.3 
Diabetes mellitus, % 10.4 7.6 0.1 11.2 3.6 6.1 2.8 1.6 
Heart rate, bpm, mean 66.6 66.5 63.0 64.7 65.7 65.8 63.1 68.0 
 
Supplementary Table 1a (continued):  Study participant characteristics 
Characteristic KORA 
S4* 
KORA 
F3* 
MICROS ORCADES RS 1* RS 2* SHIP TwinsUK PREVEND** 
N, Participants with ECG and 
genotype data 1814 
 
1644 1244 719 5974 2157 3548 2687 7500 
N, Participants after exclusion 1654 1393 1061 690 4081 1838 2985 2484 7170 
Sex, women, % 52.5 51.7 57.8 54.9 62.9 57.9 52.6 95.0 53.0 
Age, years, mean 53.5 61.4 44.2 53.3 68.3 64.8 48.1 51.3 48.7 
Age, years, range 25 – 74 35 - 79 18 – 87 18 – 92 55 - 101 55 - 95 20 – 81 17 – 83 28 – 75 
QRS interval, ms, mean 91.5 92.4 94.3 90.0 96.6 97.5 97.1 87.7 96.2 
QRS interval, ms, range 64 – 120 62 – 120 69 – 120 60 – 120 64 – 120 70-120 60 – 120 60 – 120 50 – 120 
Height, cm, mean 167.6 167.1 166.3 167.3 166.7 168.2 169.1 163.0 173.0 
BMI, kg/m2, mean 27.6 27.9 25.3 27.6 26.3 27.3 27.0 25.7 26.0 
Hypertension, % 16.6 41.6 15.5 24.9 51.8 58.5 49.5 16.4 31.1 
Diabetes mellitus, % 3.0 8.8 3.1 2.7 8.6 9.3 6.3 1.5 3.2 
Heart rate, bpm, mean 64.9 64.1 68.0 60.7 70.2 69.7 72.0 66.5 69.0 
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Supplementary Table 1b:  Study genome-wide genotyping characteristics 
Characteristic AGES ARIC BRIGHT CHS SPLIT KORCULA ERF FHS 
Array Illumina CNV370 Affy 6.0 Affy 500K 
Illumina 
CNV370 
Illumina 
CNV370 
Illumina 
CNV370 
Illumin 318K, 
370K, Affy 
250K 
Affy 500K, 
50K MIP 
Genotype calling software Bead Studio Birdseed CHIAMO Bead Studio Bead Studio Bead Studio BeadStudio BRLMM 
SNP call rate exclusion <97% <95% <95% <95% <98% <98% <98% <=97% 
SNP MAF exclusion <0.01 <1% <1% <1% <1% <1% NA <0.01 
P HWE exclusion <10x10-6 <10x10-5 <10x10-7 <10x10-5 <10x10-6 <10x10-6 <10x10-6 <10x10-6 
Imputation software Mach1 v1.0.16 Mach1 v1.0.16 IMPUTE BIMBAM Mach v1.0.15 Mach v1.0.15 Mach v1.0.15 Mach v1.0.15 
NCBI Build for imputation Build 36 Build 35 Build 35 Build 36 Build 36 Build 36 Build 36 Build 36 
GWAS statistical analysis ProbABEL, R Mach2QTL + plink SNPTEST R 
GeneABEL, 
ProbABEL, R 
GeneABEL, 
ProbABEL, R 
GeneABEL, 
ProbABEL R 
Related individuals? No No No No Yes Yes Yes Yes 
Familial adjustment method N/A N/A N/A N/A Mmscore in ProbABEL 
Mmscore in 
ProbABEL 
Mmscore in 
ProbABEL 
Kinship 
package in R 
Genomic control  factor (λ) 1.01 1.01 1.00 1.03 1.02 1.03 1.01 1.03 
 
Supplementary Table 1b (continued):   Study genome-wide genotyping characteristics 
Characteristic KORA S4 KORA F3 MICROS ORCADES RS 1 RS 2 SHIP TwinsUK 
Array Affy 6.0 Affy 500K 
Illumina 
HumHap300v
2 
Illumina 
CNV370 & 
Illumina 
HumHap300v
2 
Illumina550K 
Illumina550K 
Duo, 
610KQuad 
Affy 6.0 
Illumina 
Hap300 Duo, 
Hap300, 
Hap550, 
Hap610 
Genotype calling software Birdseed BRLMM BeadStudio Bead Studio BeadStudio GenomeStudio Birdseed Illuminus 
SNP call rate exclusion <93% <95% <98% <98% <98% <98% None <95% 
SNP MAF exclusion <1% <1% <1% <1% <1% <1% None <1% 
P HWE exclusion <10x10-5 <10x10-5 <10x10-6 <10x10-6 <10x10-6 <10x10-6 None <10x10-4 
Imputation software Mach1 v1.0.16 Mach1 v1.010 Machv1.0.16 Mach 1.0 ML Machv1.0.15 Machv1.0.16 Imputev0.5.0 Impute v0.3.2 
NCBI Build for imputation Build 36 Build 35 Build 36 Build 36 Build 36 Build 36 Build 36 Build 36 
GWAS statistical analysis ProbABEL v0.1-2 
ProbABEL 
v0.1-2 ProbABEL 
GeneABEL, 
ProbABEL, R 
Mach2QTL as 
implemented 
in GRIMP 
Mach2QTL as 
implemented 
in GRIMP 
SNPTESTv.1.
1.5 
SNPTESTv.1.
1.4 
Related individuals? No No Yes Yes No No No Yes 
Familial adjustment method N/A N/A Mmscore in ProbABEL 
Mmscore in 
ProbABEL N/A N/A N/A 
Huber-White 
robust variance 
estimation in R 
Genomic control factor (λ) 1.01 1.01 1.00 1.00 1.01 1.02 1.04 1.02 
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Supplementary Table 2:  Interaction with sex and age 
Locus Index SNP Chr Position Overall
β  
Δ (males - 
females) SE P 
Effect 
Stronger  
Age 
β SE P 
Effect 
Change 
1 rs6801957 3 38,742,319 -0.774   0.013 0.214 0.95 female   -0.0078 0.0056 0.17 increase 
 rs9851724 3 38,694,939 -0.656   0.044 0.145 0.77 female   -0.0145 0.0056 0.014 increase 
 rs11710077 3 38,632,903 0.849   -0.342 0.189 0.10 female   0.0114 0.0054 0.043 increase 
 rs11708996 3 38,608,927 0.796   0.236 0.121 0.08 male   0.0009 0.0056 0.87 increase 
2 rs9470361 6 36,731,357 0.867   -0.018 0.160 0.92 female   0.0082 0.0056 0.15 increase 
3 rs11153730 6 118,774,215 0.584 
  
0.383 0.101 0.004 male 
  -0.0539 
(0.00056)* 
0.0288 
(0.00028) 0.12 increase 
4 rs9436640 1 61,646,265 -0.596   0.053 0.166 0.76 female   -0.0094 0.0045 0.044 increase 
5 rs13165478 5 153,849,233 -0.558 
  
-0.026 0.128 0.84 male 
  0.0826 
(-0.00088)* 
0.0370 
(0.00035) 0.03 increase 
6 rs1362212 7 35,271,831 0.689   -0.101 0.151 0.52 female   0.0024 0.0047 0.61 increase 
7 rs11848785 14 71,127,108 0.494   -0.239 0.195 0.25 female   -0.0025 0.0055 0.65 decrease 
8 rs883079 12 113,277,623 0.492   -0.147 0.163 0.39 female   0.0073 0.0053 0.18 increase 
9 rs10850409 12 113,866,123 -0.488 
  
-0.237 0.212 0.29 male 
  -0.0599 
(0.00067)* 
0.0271 
(0.00026) 0.009 decrease 
10 rs7342028 10 114,469,252 -0.476   0.002 0.121 0.97 female   -0.0037 0.0039 0.36 increase 
11 rs991014 18 40,693,884 -0.415   -0.093 0.145 0.54 male   0.0033 0.0042 0.45 decrease 
12 rs17020136 2 37,101,519 0.514   0.267 0.230 0.28 male   0.0058 0.0059 0.33 increase 
13 rs4687718 3 53,257,343 -0.625   -0.382 0.226 0.13 male   0.0062 0.0059 0.30 decrease 
14 rs7562790 2 36,527,059 0.400   0.121 0.118 0.33 male   0.0062 0.0046 0.18 increase 
15 rs17391905 1 51,318,728 -1.310   -0.208 0.384 0.60 male   -0.0337 0.0115 0.005 increase 
16 rs9912468 17 61,748,819 -0.398   -0.032 0.141 0.83 male   -0.0102 0.0044 0.025 increase 
17 rs7784776 7 46,586,670 -0.386   -0.088 0.112 0.45 male   0.0083 0.0039 0.039 decrease 
18 rs4074536 1 116,112,490 -0.427   0.083 0.092 0.39 female   0.0084 0.0045 0.07 decrease 
19 rs1886512 13 73,418,187 -0.397   0.049 0.109 0.66 female   -0.0104 0.0048 0.034 increase 
20 rs2242285 3 66,514,292 0.367   -0.043 0.124 0.74 female   -0.0079 0.0044 0.08 decrease 
Interactions that are nominally significant are denoted in bold.  None of the interactions with sex or age remained significant after 
Bonferroni correction for number of tests. Effect size for QRS (Overall β) is reported in milliseconds (ms) per copy of the coded allele, and 
combines both GWAS and PREVEND results. Effect size for age (β age) is reported in ms per year. Chr, chromosome; SE, standard error. 
*Includes term for non-linear best-fit of regression model.
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Supplementary Table 3a:  Mean QRS duration and sample sizes for individuals stratified by QRS >120 ms and specific 
ventricular conduction defects 
 QRS≤120 ms (mean±sd) 
QRS >120 ms 
(mean±sd) LBBB (mean±sd) RBBB (mean±sd) NIVCD (mean±sd) 
ARIC 7996 (96.2±9.3) 213 (138.3±16.2) 26 (157.7±11.7) 62 (148.5±13.4) 125 (129.8±11.3) 
Rotterdam 4769 (96.9±10.6) 306 (143.5±17.2) 81 (157.8±12.7) 107 (148.8±14.9) 118 (129.0±8.9) 
Excludes individuals with prevalent heart failure or myocardial infarction.  sd, standard deviation; LBBB, left bundle branch block; RBBB, 
right bundle branch block; NIVCD, non-specific intraventricular conduction defect. 
 
 
Supplementary Table 3b:  Effects of a weighted genotype risk score on QRS >120 ms and stratified on specific ventricular 
conduction defects 
 QRS >120 ms LBBB RBBB NIVCD 
 OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P 
ARIC 1.12 (1.04-1.22) 0.003 1.11 (0.89-1.40) 0.34 1.00 (0.86-1.16) 0.98 1.20 (1.08-1.33) 0.0006
Rotterdam 1.04 (0.97-1.12) 0.21 1.00 (0.88-1.13) 0.97 1.02 (0.91-1.14) 0.73 1.11 (0.99-1.23) 0.07 
Combined 1.08 (1.02-1.13) 0.004 1.02 (0.92-1.14) 0.67 1.01 (0.93-1.11) 0.79 1.15 (1.07-1.25) 0.0002
Excludes individuals with prevalent heart failure or myocardial infarction. Bold indicates significant results (P < 0.05). LBBB, left bundle 
branch block; RBBB, right bundle branch block; NIVCD, non-specific intraventricular conduction defect; OR, odds ratio; CI, confidence 
interval. 
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Supplementary Table 4a: Effect of QRS duration hits on PR interval and QT interval 
Locus Nearest Gene Index SNP Chr Position 
Coded/
Non-
coded 
Allele 
QRS β QRS SE PR β 
PR 
SE PR P QT β 
QT 
SE QT P 
1 SCN10A rs6801957 3 38,742,319 T/C 0.77 0.07 3.79 0.21 1.80x10-73 -0.67 0.20 1.05x10-3 
 SCN10A rs9851724 3 38,694,939 C/T -0.66 0.07 -1.70 0.22 7.98x10-15 0.95 0.21 6.66x10-6 
 SCN5A rs11710077 3 38,632,903 T/A -0.84 0.09 -1.80 0.26 3.18x10-12 0.92 0.24 1.34x10-4 
 SCN5A rs11708996 3 38,608,927 C/G 0.79 0.10 3.04 0.29 6.00x10-26 -0.93 0.28 7.78x10-4 
2 CDKN1A rs9470361 6 36,731,357 A/G 0.87 0.08 0.74 0.24 2.01x10-3 -0.64 0.24 6.64x10-3 
3 C6orf204/SLC35F1/PLN/ BRD7P3 rs11153730 6 118,774,215 C/T 0.59 0.07 -0.56 0.20 6.20x10
-3 1.61 0.20 5.19x10-16 
4 NFIA rs9436640 1 61,585,698 G/T -0.59 0.07 0.39 0.20 0.06 -0.44 0.20 0.024 
5 HAND1/SAP30L rs13165478 5 153,849,233 A/G -0.55 0.07 0.39 0.22 0.07 -0.27 0.21 0.2 
6 TBX20 rs1362212 7 35,078,546 A/G 0.69 0.09 0.50 0.27 0.07 -0.17 0.27 0.53 
7 SIPA1L1 rs11848785 14 71,127,108 G/A -0.50 0.08 0.66 0.23 4.26x10-3 -0.09 0.22 0.67 
8 TBX5 rs883079 12 113,255,960 C/T 0.49 0.08 1.15 0.23 9.08x10-7 0.42 0.22 0.06 
9 TBX3 rs10850409 12 113,844,460 A/G -0.49 0.08 1.70 0.23 3.72x10-13 -0.33 0.23 0.15 
10 VTI1A rs7342028 10 114,469,252 T/G 0.48 0.08 0.20 0.23 0.39 -0.22 0.22 0.33 
11 SETBP1 rs991014 18 40,693,884 T/C 0.42 0.07 0.37 0.21 0.07 0.06 0.20 0.78 
12 HEATR5B/STRN rs17020136 2 37,159,666 C/T 0.51 0.08 -0.34 0.26 0.18 0.43 0.25 0.08 
13 TKT/CACNA1D/PRKCD rs4687718 3 53,257,343 A/G -0.63 0.11 -0.27 0.32 0.40 0.11 0.30 0.71 
14 CRIM1 rs7562790 2 36,585,206 G/T 0.39 0.07 -0.32 0.21 0.12 0.20 0.20 0.31 
15 C1orf185/RNF11/ CDKN2C/FAF1 rs17391905 1 51,258,161 G/T -1.35 0.23 -3.01 0.71 2.09x10
-5 -0.38 0.70 0.59 
16 PRKCA rs9912468 17 61,748,819 G/C 0.39 0.07 0.39 0.21 0.06 -0.92 0.20 3.66x10-6 
17 IGFBP3 rs7784776 7 46,393,385 G/A 0.39 0.07 0.17 0.21 0.41 0.15 0.20 0.46 
18 CASQ2 rs4074536 1 116,023,009 C/T -0.42 0.07 0.32 0.23 0.16 -0.63 0.22 4.47E-03 
19 KLF12 rs1886512 13 73,418,187 A/T -0.40 0.07 -0.40 0.22 0.06 0.28 0.22 0.19 
20 LRIG1/SLC25A26 rs2242285 3 66,514,292 A/G 0.37 0.07 0.55 0.21 8.27x10-3 0.07 0.20 0.73 
21 DKK1 rs1733724 10 53,893,983 A/G 0.49 0.09 0.03 0.29 0.92 0.84 0.28 2.46x10-3 
22 GOSR2 rs17608766 17 42,368,270 C/T 0.53 0.10 0.48 0.30 0.12 0.88 0.29 2.86x10-3 
QT interval results are drawn from the QTSCD study.12  Bold indicates significant SNPs after Bonferroni correction for the number of SNPs 
tested. The bolded allele is the coded allele.  Effect size (β) is reported in milliseconds (ms) per copy of the coded allele.  Chr, chromosome; 
AF, coded allele frequency; SE, standard error. 
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Supplementary Table 4b: Effect of PR and QT interval SNPs on QRS duration 
Trait Locus Index SNP Chr Position Coded/Non-coded Allele  Trait β Trait SE QRS β QRS SE QRS P 
PR interval SCN10A rs6800541 3 38,749,836 C/T 3.77 0.21 0.74 0.07 5.85x10-29 
 SCN5A rs11708996 3 38,608,927 C/G 3.04 0.29 0.79 0.09 1.66x10-17 
 TBX5-TBX3 rs1896312 12 113,830,807 C/T 1.95 0.23 -0.44 0.07 2.63x10-9 
 CAV1-CAV2 rs3807989 7 115,973,477 A/G 2.30 0.21 0.30 0.07 5.84x10-6 
 MEIS1 rs11897119 2 66,625,504 C/T 1.36 0.21 0.10 0.07 0.12 
 NKX2-5 rs251253 5 172,412,942 C/T -1.49 0.21 0.10 0.07 0.13 
 SOX5 rs11047543 12 24,679,606 A/G -2.09 0.29 0.10 0.09 0.29 
 ARHGAP24 rs7692808 4 86,860,173 A/G -2.01 0.22 -0.04 0.07 0.60 
 WNT11 rs4944092 11 75,587,267 G/A -1.19 0.22 0.04 0.07 0.60 
QT interval SCN5A rs11129795 3 38,568,397 A/G -1.27 0.23 0.78 0.08 1.95x10-24 
 PLN rs11970286 6 118,787,067 T/C 1.64 0.20 0.55 0.07 7.07x10-17 
 PLN rs12210810 6 118,759,897 C/G -3.13 0.43 -0.75 0.15 4.08x10-7 
 NOS1AP rs12143842 1 160,300,514 T/C 2.88 0.23 -0.29 0.08 1.25x10-4 
 ATP1B1 rs10919071 1 167,366,107 G/A -2.05 0.29 -0.21 0.10 0.03 
 LIG3 rs2074518 17 30,356,290 T/C -1.23* 0.18* -0.10 0.07 0.12 
 KCNJ2 rs17779747 17 66,006,587 T/G -1.16 0.21 -0.10 0.07 0.15 
 KCNE1 rs1805128 21 34,743,550 T/C 4.03* 1.58* -0.29 0.22 0.19 
 KCNH2 rs4725982 7 150,268,796 T/C 1.58* 0.35* -0.10 0.08 0.24 
 NOS1AP rs4657178 1 160,477,234 T/C 2.19 0.22 -0.08 0.07 0.27 
 KCNQ1 rs12296050 11 2,445,918 T/C 1.44 0.25 -0.06 0.08 0.45 
 NDRG4 rs7188697 16 57,179,679 G/A -1.66 0.23 -0.06 0.08 0.46 
 KCNH2 rs2968863 7 150,254,070 T/C -1.35 0.23 0.05 0.08 0.55 
 KCNQ1 rs2074238 11 2,441,379 T/C -8.22* 1.05* 0.18 0.34 0.59 
 RNF207 rs846111 1 6,201,957 C/G 1.49 0.25 -0.04 0.09 0.66 
 LITAF rs8049607 16 11,599,254 T/C 1.25 0.22 -0.01 0.07 0.88 
QT results are drawn from the QTSCD study, unless otherwise noted. 12  PR results are from.13  Bold indicates significant SNPs after 
Bonferroni correction for the number of SNPs tested. The bolded allele is the coded allele.  Effect size (β) is reported in milliseconds (ms) 
per copy of the coded allele.  Chr, chromosome; MAF, minor allele frequency; SE, standard error. *Genome-wide significant results 
(P<5x10-8) are drawn from the QTGEN study, 11 and standardized beta estimates and SE were converted to ms using SD=17.5 ms.   
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Supplementary Table 5: Gene specific primers used in the animal studies 
 Sense Anti-sense 
SCN10A 5’-AATCAGAGCGAGGAGAAGAC-3’ 5’-CTAGTGAGCTAAGGATCGCA-3’ 
S26 5’-GCCATCCATAGCAAGGTTGT-3’ 5’-GCCTCTTTACATGGGCTTTG-3’ 
 
